Analyst Price Targets — IBRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 8, 2026 11:24 am | — | BTIG | $12.00 | $7.76 | TheFly | ImmunityBio price target lowered to $12 from $13 at BTIG |
| March 4, 2026 12:54 pm | Edward Tenthoff | Piper Sandler | $12.00 | $9.20 | StreetInsider | Immunitybio Inc (IBRX) PT Raised to $12 at Piper Sandler |
| February 23, 2026 5:43 pm | — | H.C. Wainwright | $15.00 | $9.71 | TheFly | ImmunityBio price target raised to $15 from $10 at H.C. Wainwright |
| January 20, 2026 11:49 am | — | Piper Sandler | $7.00 | $5.52 | TheFly | ImmunityBio price target raised to $7 from $5 at Piper Sandler |
| January 10, 2025 11:49 am | Justin Zelin | BTIG | $6.00 | $2.42 | TheFly | ImmunityBio initiated with a Buy at BTIG |
| August 3, 2022 9:24 am | Kelly Shi | Jefferies | $8.00 | $4.13 | TheFly | Jefferies starts ImmunityBio at Buy on Anktiva potential, IO pipeline |
Latest News for IBRX
ImmunityBio offers a best-in-class, approved immunotherapy, ANKTIVA, driving rapid revenue growth and significant market share in NMIBC. IBRX's pipeline is robust, with multiple Phase 1-3 trials targeting NSCLC, glioblastoma, HIV, and other high-value indications, supporting long-term upside. The recent 40% pullback from 52-week highs creates an attractive entry point, with strong balance sheet support and no…
Short‑interest screens are lighting up with a tight cluster of mid‑ and large‑cap names where bearish bets have gone all‑in, turning these stocks into live‑wire squeeze candidates rather than sleepy laggards.
Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run.
ImmunityBio is pivoting from a single-product Anktiva focus to a broad immunotherapy platform, emphasizing memory-like cytokine-enriched NK cells (M-ceNK). Key near-term catalysts include the pivotal QUILT-2.005 bladder cancer trial, lymphopenia indication expansion, and the glioblastoma (GBM) program, each validating the immune-restoration thesis. IBRX trades at a significant premium (65x trailing sales, 44x…
ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IBRX.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.